To Disclose or Not To Disclose: Federal Government & Cybersecurity Vulnerabilities
Client Alert | 1 min read | 11.16.17
On November 15, 2017, the White House Cybersecurity Coordinator, Rob Joyce, announced a formative cybersecurity policy entitled “Vulnerabilities Equities Policy and Process for the United States Government.”
According to the policy, the primary focus is to “prioritize the public's interest in cybersecurity and to protect core Internet infrastructure, information systems, critical infrastructure systems, and the U.S. economy through the disclosure of vulnerabilities discovered by the United States Government (USG).” The Vulnerabilities Equities Process (VEP) balances dissemination of vulnerability information (e.g., zero day exploits) to the vendor/supplier in the expectation that it will be patched with temporarily restricting the knowledge of the vulnerability to the USG, and potentially other partners, so that it can be used for national security and law enforcement purposes, such as intelligence collection, military operations, and/or counterintelligence. In striking this balance, the policy aims to increase transparency regarding the process for the public and businesses, and also signals that the US will join with several countries that have announced formal policies in this area regarding management of vulnerabilities. Interestingly, this policy expands the management of vulnerabilities to include a broad array of national security and intelligence agencies.
This policy supersedes the Commercial and Government Information Technology and Industrial Control Product or System Vulnerabilities Equities Policy and Process, dated February 16, 2010.
This policy applies to all USG components and personnel and contractors and includes Government off-the-shelf (GOTS), Commercial off-the-shelf (COTS), or other commercial information systems (to include open-source software), Industrial Control Systems (ICS) or products, and associated systems such as Supervisory Control and Data Acquisition (SCADA) and Distributed Control Systems (DCS).
Businesses and the public will likely be interested in the annual public reporting that is promised, which may include statistics about how many vulnerabilities go through the process and even potentially how long they are withheld from disclosure.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
